An official website of the United States government
Home
Name
Rindopepimut
Alternate Names
CDX-110
Rintega
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Vaccination
NSC Number
None
Primary Site
Brain
Histology
Glioblastoma Multiforme
Remarks
Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme (GBM) that test positive for the epidermal growth factor receptor (EGFR) variant (EGFRvIII). this drug is currently in phase III clinical trials and has not received final FDA approval as of December 2015.
Coding information: Until Rindopepimut receives final FDA approval, code in Other Treatment and assign code 2. If approval if granted, then this agent will be coded as BRM/Immunotherapy.
Coding information: Until Rindopepimut receives final FDA approval, code in Other Treatment and assign code 2. If approval if granted, then this agent will be coded as BRM/Immunotherapy.
Coding
Please see remarks for additional information
